Wellington Management Group LLP Acquires Shares of 169,934 Evolus, Inc. $EOLS

Wellington Management Group LLP bought a new stake in shares of Evolus, Inc. (NASDAQ:EOLS) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 169,934 shares of the company’s stock, valued at approximately $1,179,000. Wellington Management Group LLP owned approximately 0.26% of Evolus at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of EOLS. Nantahala Capital Management LLC purchased a new position in Evolus in the second quarter valued at about $38,878,026. BlackRock Inc. acquired a new stake in Evolus during the 2nd quarter valued at approximately $33,595,000. Braidwell LP purchased a new stake in Evolus during the 4th quarter worth approximately $20,650,000. Rice Hall James & Associates LLC purchased a new stake in Evolus during the 2nd quarter worth approximately $8,952,000. Finally, Perceptive Advisors LLC acquired a new position in shares of Evolus in the 1st quarter valued at approximately $5,289,000. 90.69% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, insider David Moatazedi sold 105,108 shares of Evolus stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $9.04, for a total value of $950,176.32. Following the completion of the transaction, the insider owned 499,592 shares in the company, valued at approximately $4,516,311.68. This trade represents a 17.38% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 5.00% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several equities analysts have recently commented on EOLS shares. Wall Street Zen upgraded Evolus from a “hold” rating to a “buy” rating in a research note on Saturday, August 8th. BTIG Research restated a “buy” rating and issued a $13.00 price target on shares of Evolus in a research note on Wednesday, June 17th. HC Wainwright reaffirmed a “buy” rating and issued a $13.00 price target on shares of Evolus in a report on Tuesday, August 25th. Finally, Weiss Ratings upgraded shares of Evolus from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, June 15th. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Evolus currently has a consensus rating of “Moderate Buy” and an average price target of $14.50.

Evolus Stock Performance

NASDAQ:EOLS opened at $7.84 on Friday. The company has a market capitalization of $517.83 million, a price-to-earnings ratio of -15.08 and a beta of 1.42. Evolus, Inc. has a one year low of $3.86 and a one year high of $9.31. The stock has a 50-day simple moving average of $7.42 and a 200 day simple moving average of $6.23.

About Evolus

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.